Peter Huber is a senior fellow at the Manhattan Institute writing on the issues of drug development, energy, technology, and the law. Before joining the Manhattan Institute, Huber served as an assistant and later associate professor at MIT for six years. He clerked on the D.C. Circuit Court of Appeals for Ruth Bader Ginsburg, and then on the U.S. Supreme Court for Sandra Day O'Connor. Huber also is a partner at the Washington, D.C. law firm of Kellogg, Huber, Hansen and Todd. He is the author of The Bottomless Well (2005), co-authored with Mark P. Mills, and the forthcoming book, The Cure in the Code: How 20th Century Law is Undermining 21st Century Medicine. Huber earned his law degree from Harvard University and a doctorate in mechanical engineering from MIT. Huber has previously debated in Major Reductions in Carbon Emissions are Not Worth the Money.
More About Peter Huber
Cellular intervention to slow aging is a science in its infancy. Will regulators keep it there forever?
Government-controlled vaccine development has left us scarily vulnerable.
The new medicine shows that were biochemically separate and unequaland regulators are starting to catch on.
Brilliant doctors often work closely with big drug companies, and they seem to like their corporate partners just fine.
The new pharmacopoeia offers people too much knowledge and control for one-size-fits-all health care to cope with.
Diagnostic technology is on a collision course with the FDA.
Big drug companies shun some drugs and embrace others because, collectively, the FDA, doctors, patients, insurers, and juries push costs higher, and prices lower, on some categories of drugs and not on others, to the point where some make economic sense and some do not.